Aurinia Pharmaceuticals Inc. AUPH

Latest FY: 2025 Healthcare Biotechnology
Market Price $15.47
Market Cap $1.95B
P/E Ratio 7.48
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑20.4% YoY
$283.06M
3-Yr CAGR: 28.3%
Net Income ↑4,893.1% YoY
$287.20M
Net Margin: 101.5%
Free Cash Flow ↑207.0% YoY
$135.41M
FCF Yield: 6.93%
EPS (Diluted) ↑5,075.0% YoY
$2.07
Basic: $2.14
Return on Equity Efficiency
49.4%
ROA: 58.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (AUPH)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (+142.8%) is identical to Gross Profit YoY (+142.8%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
  • FY 2018: Revenue YoY (+10.2%) is identical to Gross Profit YoY (+10.2%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $0.2M $0.2M $-25.0M $-0.66 $-18.7M
FY 2017 $0.4M +142.8% $0.4M $-46.9M -87.3% $-0.92 -39.4% $-41.2M $-41.2M
FY 2018 $0.5M +10.2% $0.4M $-64.0M -36.7% $-0.76 +17.4% $-51.6M $-51.6M -25.4%
FY 2019 $0.3M -31.3% $0.3M $-123.7M -93.1% $-1.33 -75.0% $-63.5M $-63.5M -23.0%
FY 2020 $50.1M +15,660.4% $44.2M $-102.7M +17.0% $-69.9M
FY 2021 $45.6M -9.0% $44.5M $-181.0M -76.2% $-1.40 $-157.7M $-157.7M
FY 2022 $134.0M +193.9% $128.4M $-108.2M +40.2% $-0.76 +45.7% $-79.5M $-79.5M +49.6%
FY 2023 $175.5M +31.0% $161.4M $-78.0M +27.9% $-0.54 +28.9% $-33.5M $-34.2M +57.0%
FY 2024 $235.1M +34.0% $206.9M $5.8M +107.4% $0.04 +107.4% $44.4M $44.1M +229.0%
FY 2025 $283.1M +20.4% $250.4M $287.2M +4,893.1% $2.07 +5,075.0% $135.7M $135.4M +207.0%
$

Valuation

Market Price $15.47
Market Cap $1.95B
Enterprise Value N/A
P/E Ratio 7.48
P/B Ratio 3.42
FCF Yield 6.93%
Dividend Yield N/A
Shares Outstanding 128,601,700
%

Profitability & Margins

Gross Margin 88.46%
Operating Margin 37.06%
Net Margin 101.47%
Return on Equity (ROE) 49.40%
Return on Assets (ROA) 58.38%
Asset Turnover 0.58x
Revenue 3-Yr CAGR 28.30%
🛡️

Financial Health & Liquidity

Current Ratio 7.38
Cash Ratio 1.20
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $80.16M
Total Debt N/A
Book Value / Share $4.52
💧

Cash Flow Efficiency

Operating Cash Flow $135.66M
Capital Expenditures (CapEx) $252.00K
Free Cash Flow $135.41M
OCF / Revenue 47.93%
FCF / Revenue 47.84%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $2.07
EPS (Basic) $2.14
Dividends / Share N/A
Book Value / Share $4.52
EPS YoY Growth 5,075.00%
🏛️

Balance Sheet (FY 2025)

Total Assets $491.97M
Total Liabilities $66.62M
Stockholders' Equity $581.33M
Current Assets $491.97M
Current Liabilities $66.62M